Search Results - "Gupta, Rishab K."

Autoantibody cancer biomarker : Extracellular protein kinase a by NESTEROVA, Maria V, JOHNSON, Natalie, CHEADLE, Christopher, BATES, Susan E, MANI, Sridhar, STRATAKIS, Constantine A, KAHN, Islam, GUPTA, Rishab K, CHO-CHUNG, Yoon S

“…In cancer cells, cyclic AMP-dependent protein kinase (PKA) is secreted into the conditioned medium. This PKA, designated as extracellular protein kinase A…”
Get full text

Enhanced Humoral Immune Response Correlates With Improved Disease-Free and Overall Survival in American Joint Committee on Cancer Stage II Melanoma Patients Receiving Adjuvant Polyvalent Vaccine by DIFRONZO, L. Andrew, GUPTA, Rishab K, ESSNER, Richard, FOSHAG, Leland J, O'DAY, Steven J, WANEK, Leslie A, STERN, Stacey L, MORTON, Donald L

“…Although the improved overall survival (OS) of patients who receive Canvaxin (CancerVax Corp, Carlsbad, CA) polyvalent vaccine (PV) immunotherapy for…”
Get full text

Humoral Immune Response to a Therapeutic Polyvalent Cancer Vaccine After Complete Resection of Thick Primary Melanoma and Sentinel Lymphadenectomy by CHUNG, Mathew H, GUPTA, Rishab K, HSUEH, Eddy, ESSNER, Richard, WEI YE, YEE, Reynold, MORTON, Donald L

“…A therapeutic polyvalent cancer vaccine (Canvaxin vaccine; CancerVax Corp, Carlsbad, CA) induces antibodies to a glycoprotein tumor-associated antigen (TA90)…”
Get full text

Tumor-Associated Antigen TA90 Immune Complex Assay Predicts Recurrence and Survival After Surgical Treatment of Stage I-III Melanoma by KELLEY, Mark C, GUPTA, Rishab K, HSUEH, Eddy C, YEE, Reynold, STERN, Stacey, MORTON, Donald L

“…Immune complexes (IC) containing the tumor-associated antigen TA90 can be identified in the sera of melanoma patients. We have shown that an enzyme-linked…”
Get full text

Prolonged survival of patients receiving active immunotherapy with Canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes by Morton, Donald L, Hsueh, Eddy C, Essner, Richard, Foshag, Leland J, O'Day, Steven J, Bilchik, Anton, Gupta, Rishab K, Hoon, Dave S B, Ravindranath, Mepur, Nizze, J Anne, Gammon, Guy, Wanek, Leslie A, Wang, He-Jing, Elashoff, Robert M

“…To determine whether adjuvant postoperative active specific immunotherapy with a therapeutic polyvalent vaccine (PV) called Canvaxin can prolong survival…”
Get full text

A Comparison of 3 Tumor Markers (MIA, TA90IC, S100B) in Stage III Melanoma Patients by Faries, Mark B., Gupta, Rishab K., Ye, Xing, Lee, Christopher, Yee, Reynold, Leopoldo, Zacharias, Essner, Richard, Foshag, Leland J., Elashoff, David, Morton, Donald L.

“…Purpose: There is no consensus regarding the optimal tumor markers for melanoma. We compared 3 tumor markers, TA90-immune complex (TA90IC), melanoma-inhibiting…”
Get full text

CancerVax, an allogeneic tumor cell vaccine, induces specific humoral and cellular immune responses in advanced colon cancer by Habal, N, Gupta, R K, Bilchik, A J, Yee, R, Leopoldo, Z, Ye, W, Elashoff, R M, Morton, D L

“…The immunogenicity of the polyvalent tumor cell vaccine CancerVax has been correlated with the survival of patients receiving active immunotherapy for…”
Get full text

Endogenous immune response to early- and intermediate-stage melanoma is correlated with outcomes and is independent of locoregional relapse and standard prognostic factors by Litvak, David A, Gupta, Rishab K, Yee, Reynold, Wanek, Leslie A, Ye, Wei, Morton, Donald L

“…Standard prognostic factors, including precise staging of the regional lymph nodes, cannot accurately determine which early-stage melanomas will metastasize…”
Get full text

Does endogenous immune response determine the outcome of surgical therapy for metastatic melanoma? by Hsueh, E C, Gupta, R K, Yee, R, Leopoldo, Z C, Qi, K, Morton, D L

“…Although the presence of tumor cells in the blood of patients with metastatic melanoma suggests widely disseminated disease, many of these patients enjoy…”
Get full text

Cytoreductive surgery and adjuvant immunotherapy: a new management paradigm for metastatic melanoma by Morton, D. L, Ollila, D. W, Hsueh, E. C, Essner, R, Gupta, R. K

“…Although patients with metastatic disease are usually not offered surgery as part of their comprehensive treatment plan, the authors suggest that surgical…”
Get full text

Melanoma-inhibiting activity assay predicts survival in patients receiving a therapeutic cancer vaccine after complete resection of American Joint Committee on Cancer Stage III Melanoma by Faries, Mark B, Gupta, Rishab K, Ye, Xing, Hsueh, Eddy C, Morton, Donald L

“…More than half of melanoma patients rendered disease free by lymph node dissection will experience disease recurrence. We hypothesized that serum levels of…”
Get full text

Androgen blockade enhances response to melanoma vaccine by HSUEH, Eddy C, GUPTA, Rishab K, LEFOR, Alan, REYZIN, Gary, WEI YE, MORTON, Donald L

“…Because preclinical studies suggest an interaction between androgens and the immune system, we used a murine model to determine whether androgen blockade with…”
Get full text

Identification of a natural killer enhancing factor (NKEF) from human erythroid cells by Shau, H, Gupta, R K, Golub, S H

“…We have previously shown that RBC significantly augment NK cell-mediated cytotoxicity when added at the initiation of cytotoxicity assays. We now report that…”
Get more information

Serum TA90 immune complex assay can predict outcome after resection of thick (> or =4 mm) primary melanoma and sentinel lymphadenectomy by Chung, Mathew H, Gupta, Rishab K, Essner, Richard, Ye, Wei, Yee, Reynold, Morton, Donald L

“…We hypothesized that the postoperative serum level of TA90-IC, an immune complex of a 90-kDa tumor-associated antigen and its antibody, might have a…”
Get full text

Enhancement of complement-dependent cytotoxicity by polyvalent melanoma cell vaccine (CancerVax): correlation with survival by Hsueh, E C, Famatiga, E, Gupta, R K, Qi, K, Morton, D L

“…Case control studies have demonstrated that administration of CancerVax, a polyvalent melanoma cell vaccine (PMCV), after complete resection of melanoma…”
Get full text

TA90-IC, a new marker for advanced colon cancer by Habal, N, Gupta, R K, Bilchik, A J, Johnson, T, Morton, D L

“…Although carcinoembryonic antigen (CEA) is the most frequently used marker for colon cancer, it is elevated in only 70% of patients with advanced disease and…”
Get full text

Positron emission tomography plus serum TA90 immune complex assay for detection of occult metastatic melanoma by Hsueh, Eddy C, Gupta, Rishab K, Glass, Edwin C, Yee, Reynold, Qi, Karen, Morton, Donald L

“…Background: Whole-body positron emission tomography (PET) using 18F-fluorodeoxyglucose is very sensitive for detection of metastatic melanoma. We previously…”
Get full text

Abstract 2658: GPEx® system to increase production of pritumumab in a CHO cell line by Bleck, Gregory T., Gupta, Rishab K., Kotlan, Beatrix, York, Dona, Glassy, Mark C.

“…Pritumumab, a natural human IgG1 kappa antibody isolated from a lymph node of a patient with cervical carcinoma, has been used in a Phase II setting with brain…”
Get full text

Serum total gangliosides and TA90-IC levels: novel immunologic markers in colorectal cancer by Perez, Carlos A, Ravindranath, Mepur H, Gupta, Rishab K, Tollenaar, Rob A E M, van de Velde, Cornelius J, Wood, Thomas F, Soh, Daniel, Morton, Donald L, Bilchik, Anton J

“…Because of the challenge in defining prognostic markers predictive of recurrence or progression, carcinoembryonic antigen (CEA) remains the most frequently…”
Get full text

Preoperative serum TA90-IC as an adjunct to serum CA 19-9 in the diagnosis of pancreatic malignancy: A pilot study by Chung, Mathew H., Gupta, Rishab K., Bilchik, Anton J., Ye, Wei, Yee, Reynold, Morton, Donald L.

“…Because TA90, a 90-kDa immunogenic tumor-associated antigen, is expressed by pancreatic cancer cells, we hypothesized that the serum level of its immune…”
Get full text